Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Taysha Gene Therapies, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases. Its 8-K reports furnish financial results, business highlights, TSHA-102 clinical and regulatory updates, program-rights announcements, and exhibits tied to company press releases.
The filing record also includes proxy materials for annual stockholder meetings, director elections and voting matters, as well as material definitive agreement disclosures involving common-stock sales arrangements. Cover-page disclosures identify TSHA common stock, par value and Nasdaq listing status, while proxy filings provide formal governance and stockholder-meeting information.
Taysha Gene Therapies insider files to sell shares under Rule 144. Emily McGinnis filed a notice to sell 901 shares of Taysha Gene Therapies common stock through Maxim Group LLC on or about 02/04/2026 on Nasdaq. These 901 shares were acquired on 02/03/2026 via an RSU award that vested and settled in stock as compensation for continued employment.
The notice reports that 273,919,373 shares of common stock were outstanding. Over the prior three months, McGinnis sold 25,119 shares for gross proceeds of $119,315.25 and 7,586 shares for $34,971.46. By signing, the seller represents not knowing any undisclosed material adverse information about the company.
Taysha Gene Therapies insider Frederick Porter plans to sell 889 shares of common stock through Maxim Group on Nasdaq around 02/04/2026, with an aggregate market value of $4,196.08.
The shares were acquired on 02/03/2026 via a vested RSU award, granted in stock as compensation for continued employment. The notice states 273,919,373 shares of common stock outstanding. Over the prior three months, Porter sold 43,003 shares for $204,264.25 and 12,987 shares for $59,870.07.
Taysha Gene Therapies insider Sean McAuliffe has filed to sell additional company stock. The notice covers 914 shares of common stock, to be sold through Maxim Group LLC on or around February 4, 2026 on Nasdaq, with an aggregate market value of $4,314.08. The filing states that 273,919,373 shares of common stock were outstanding.
The 914 shares come from a restricted stock unit award acquired on February 3, 2026, which vested and was settled in stock as compensation for continued employment. In the past three months, McAuliffe also sold 36,071 shares for $171,337.25 and 10,894 shares for $50,221.34.
Taysha Gene Therapies insider plans small stock sale under Rule 144. A person associated with the company filed to sell 697 shares of common stock through Maxim Group LLC on Nasdaq, with an aggregate market value of $3,289.84, against 273,919,373 shares outstanding.
The shares were acquired on 02/03/2026 via a restricted stock unit (RSU) award that vested and settled in stock in exchange for continued employment. During the prior three months, the same seller disposed of 23,533 shares for $111,781.75 and 7,107 shares for $32,763.27.
Taysha Gene Therapies, Inc. insider Kamran Alam has filed a Rule 144 notice to sell 1,655 shares of common stock through broker Maxim Group LLC on or about 02/04/2026, with an aggregate market value of 7,811.6. The company had 273,919,373 common shares outstanding.
The 1,655 shares to be sold were acquired on 02/03/2026 via an RSU award from the issuer, vesting and settling in stock as compensation for continued employment. In the past three months, Alam previously sold 78,968 and 23,849 common shares for gross proceeds of 375,098.00 and 109,943.89, respectively.
Taysha Gene Therapies President and Head of R&D Nagendran Sukumar reported routine share sales tied to tax withholding. On January 23, 2026, he sold 89,132 shares of common stock at a weighted average price of $4.75. On January 26, 2026, he sold an additional 26,918 shares at a weighted average price of $4.61.
According to the disclosure, these transactions were part of a mandatory sell-to-cover arrangement used solely to satisfy income tax liabilities from vesting restricted stock unit awards. After the reported sales, Sukumar beneficially owned 1,317,389 shares of Taysha Gene Therapies common stock directly.
Taysha Gene Therapies, Inc. Chief Executive Officer and director Nolan Sean P. reported routine stock sales tied to tax withholding on vested equity. On January 23, 2026, he sold 136,789 shares of common stock at a weighted average price of $4.75, and on January 26, 2026 he sold an additional 41,312 shares at a weighted average price of $4.61. According to the disclosure, these transactions were executed under a mandatory sell-to-cover arrangement to satisfy income tax liabilities from restricted stock unit vesting.
Following these sales, Nolan directly beneficially owned 2,908,257 shares of Taysha common stock and indirectly beneficially owned 1,535,545 shares held through Nolan Capital, LLC, where he serves as President with shared voting and investment power.
Taysha Gene Therapies, Inc. chief financial officer Kamran Alam reported sales of company common stock tied to tax withholding on vested equity awards. On January 23, 2026, he sold 78,968 shares of common stock at a weighted average price of $4.75 per share. On January 26, 2026, he sold an additional 23,849 shares at a weighted average price of $4.61 per share. A footnote states these transactions were part of a mandatory sell-to-cover arrangement to satisfy income tax liabilities from the vesting of restricted stock unit awards. After these transactions, Alam beneficially owned 1,443,786 shares of Taysha common stock directly.
Taysha Gene Therapies insider plans Rule 144 sale of stock. A holder has filed to sell 168,078 shares of Taysha Gene Therapies common stock through broker Maxim Group LLC on or about 01/23/2026, with an indicated aggregate market value of $855,517.02. The filing notes that 273,919,373 shares of common stock were outstanding, providing context for the size of the planned sale. The shares to be sold were acquired on 01/23/2026 via a restricted stock unit (RSU) award from the issuer, which vested and was settled in stock as compensation for the reporting person’s continued service as an employee.
TSHA insider files notice to sell common stock under Rule 144. A Form 144 was filed for the planned sale of 113,824 shares of TSHA common stock through broker Maxim Group LLC on Nasdaq, with an aggregate market value of $579,364.16. The filing notes 273,919,373 shares of TSHA common stock outstanding. The shares to be sold were acquired on 01/23/2026 via an RSU award from the issuer, vesting and settling in stock in exchange for the reporting person’s continued service.
The filer also reported prior TSHA stock sales in the past three months: 110,125 shares of common stock sold on 11/28/2025 for gross proceeds of $522,774.39, and 200,000 shares sold on 01/12/2026 for gross proceeds of $942,738.11. By signing the notice, the person for whose account the securities are to be sold represents that they do not know any undisclosed material adverse information about the issuer’s operations.